Want to see GB:NFX full AI Analyst Report?
NFX Stock Chart & Stats
0.23 p
<0.01 p(2.11%)
At close: 4:00 PM EST
0.23 p
<0.01 p(2.11%)
Day’s Range― - ―
52-Week Range0.07 p - 0.56 p
Previous CloseN/A
Volume1.00M
Average Volume (3M)97.88M
Market Cap
£4.70M
Enterprise Value2.97M
Total Cash (Recent Filing)£930.28K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)6.0
Beta0.01
Next Earnings
Feb 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,609,750,000
10 Day Avg. Volume69,476,590
30 Day Avg. Volume97,880,797
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-6.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Cocrystal TechnologyA proprietary cocrystal platform is a durable strategic asset: it enables reformulation of existing APIs to improve stability and bioavailability, supports multiple programs and licensing opportunities, and provides a repeatable product-development pathway that can sustain long-term commercial and partnering value.
Very Low Leverage / Debt-freeA debt-free capital structure materially reduces fixed financial obligations and interest risk, giving management flexibility to seek non-debt funding, time to execute development milestones, and greater negotiating power with partners; this lower financial risk is a long-lived structural strength.
Extremely Lean Operating FootprintA very small headcount keeps fixed operating costs low and enables the company to conserve cash while outsourcing lab and clinical work; this lean model extends runway between financings and supports focused R&D spending, a durable operational advantage for a pre-revenue biotech.
Bears Say
No Recent Revenue / Stalled CommercializationZero revenue across multiple years indicates an absence of commercialized products or meaningful licensing income; this structural lack of commercialization undermines self-sustaining cash generation, increases dependence on external funding, and leaves long-term viability contingent on successful product development or deals.
Persistent Cash Burn And Negative Free Cash FlowConsistent negative operating and free cash flow demonstrates ongoing funding needs and creates structural dilution or financing risk; persistent cash burn constrains the company's ability to progress clinical work, hire capabilities, or invest in scale without recurring capital raises over the medium term.
Shrinking Equity And Asset BaseA materially reduced equity and asset base leaves a smaller financial buffer for setbacks, increases insolvency risk in adverse scenarios, and limits capacity to self-fund development or invest in scale; this structural erosion reduces strategic optionality and weakens counterparties' confidence.
Nuformix Plc News
NFX FAQ
What was Nuformix Plc’s price range in the past 12 months?
Nuformix Plc lowest share price was 0.07 p and its highest was 0.56 p in the past 12 months.
What is Nuformix Plc’s market cap?
Nuformix Plc’s market cap is £4.70M.
When is Nuformix Plc’s upcoming earnings report date?
Nuformix Plc’s upcoming earnings report date is Feb 03, 2027 which is in 215 days.
How were Nuformix Plc’s earnings last quarter?
Nuformix Plc released its earnings results on May 28, 2026. The company reported 0 p earnings per share for the quarter, the consensus estimate of N/A by 0 p.
Is Nuformix Plc overvalued?
According to Wall Street analysts Nuformix Plc’s price is currently Overvalued.
Does Nuformix Plc pay dividends?
Nuformix Plc does not currently pay dividends.
What is Nuformix Plc’s EPS estimate?
Nuformix Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nuformix Plc have?
Nuformix Plc has 2,609,750,000 shares outstanding.
What happened to Nuformix Plc’s price movement after its last earnings report?
Nuformix Plc reported an EPS of 0 p in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -2.941%.
Which hedge fund is a major shareholder of Nuformix Plc?
Currently, no hedge funds are holding shares in GB:NFX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuformix Plc
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Technical Analysis
Evgen Pharma
―
Futura Medical
―
ImmuPharma
―
OptiBiotix Health
―
HemoGenyx Pharmaceuticals Plc
―